Novel Challenges and Therapeutic Options for Liver Diseases
This Special Issue focuses on cutting-edge developments, from viral diseases via autoimmune, vascular, metabolic disorders, to liver cirrhosis and its complications, such as acute and chronic hepatic failure and the development of primary liver cell carcinoma. Digitalization, prevention, and telemed...
Gorde:
| Formatua: | Online |
|---|---|
| Hizkuntza: | ingelesa |
| Argitaratua: |
MDPI - Multidisciplinary Digital Publishing Institute
2024
|
| Gaiak: | |
| Sarrera elektronikoa: | ONIX_20240704_9783725815289_233 |
| Etiketak: |
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|
| _version_ | 1869531274839851008 |
|---|---|
| collection | Directory of Open Access Books |
| description | This Special Issue focuses on cutting-edge developments, from viral diseases via autoimmune, vascular, metabolic disorders, to liver cirrhosis and its complications, such as acute and chronic hepatic failure and the development of primary liver cell carcinoma. Digitalization, prevention, and telemedicine are also included. Finally, this Special Issue gives new insights in future translational hepatology. |
| format | Online |
| id | doab-20.500.12854ir-139437 |
| institution | Directory of Open Access Books |
| language | eng |
| publishDate | 2024 |
| publishDateRange | 2024 |
| publishDateSort | 2024 |
| publisher | MDPI - Multidisciplinary Digital Publishing Institute |
| publisherStr | MDPI - Multidisciplinary Digital Publishing Institute |
| record_format | ojs |
| spelling | doab-20.500.12854ir-1394372024-07-04T09:55:10Z Novel Challenges and Therapeutic Options for Liver Diseases Gerken, Guido microbiome obesity metabolic syndrome fecal microbiota transplantation ROTEM® TIPS liver disease thrombosis risk assessment hypercoagulable state portal hypertension hepatic decompensation chronic hepatitis B chronic hepatitis C chronic hepatitis D antiviral therapy liver cirrhosis DAA therapy functional cure HBsAg loss hepatology liver transplantation decompensated cirrhosis acute-on-chronic liver failure NASH pNRF2 SOCS3 immunohistochemistry UDCA bile acid transporter ALT GGT TE neuroendocrine transplantation outcomes liver metastases systematic review prevention management telemedicine metabolic dysfunction-associated fatty liver disease monitor lifestyle modification COVID-19 pandemic NUC treatment low-level HBsAg carriers therapeutic vaccination third generation pre-S/S vaccine long-term observation hepatocellular carcinoma HCC MASLD MASH NAFLD biomarker intestinal microbiota chronic hepatitis b HBsAg seroconversion seroclearance history of hepatology MASLD/NAFLD liver fibrosis/cirrhosis chronic viral hepatitides liver–microbiome axis organokine crosstalk chronobiology liver aging thema EDItEUR::P Mathematics and Science::PS Biology, life sciences This Special Issue focuses on cutting-edge developments, from viral diseases via autoimmune, vascular, metabolic disorders, to liver cirrhosis and its complications, such as acute and chronic hepatic failure and the development of primary liver cell carcinoma. Digitalization, prevention, and telemedicine are also included. Finally, this Special Issue gives new insights in future translational hepatology. 2024-07-04T09:55:07Z 2024-07-04T09:55:07Z 2024 book ONIX_20240704_9783725815289_233 9783725815289 9783725815272 https://directory.doabooks.org/handle/20.500.12854/139437 eng application/octet-stream Attribution-NonCommercial-NoDerivatives 4.0 International https://mdpi.com/books/pdfview/book/9439 https://mdpi.com/books/pdfview/book/9439 MDPI - Multidisciplinary Digital Publishing Institute 10.3390/books978-3-7258-1527-2 10.3390/books978-3-7258-1527-2 46cabcaa-dd94-4bfe-87b4-55023c1b36d0 9783725815289 9783725815272 182 open access |
| spellingShingle | microbiome obesity metabolic syndrome fecal microbiota transplantation ROTEM® TIPS liver disease thrombosis risk assessment hypercoagulable state portal hypertension hepatic decompensation chronic hepatitis B chronic hepatitis C chronic hepatitis D antiviral therapy liver cirrhosis DAA therapy functional cure HBsAg loss hepatology liver transplantation decompensated cirrhosis acute-on-chronic liver failure NASH pNRF2 SOCS3 immunohistochemistry UDCA bile acid transporter ALT GGT TE neuroendocrine transplantation outcomes liver metastases systematic review prevention management telemedicine metabolic dysfunction-associated fatty liver disease monitor lifestyle modification COVID-19 pandemic NUC treatment low-level HBsAg carriers therapeutic vaccination third generation pre-S/S vaccine long-term observation hepatocellular carcinoma HCC MASLD MASH NAFLD biomarker intestinal microbiota chronic hepatitis b HBsAg seroconversion seroclearance history of hepatology MASLD/NAFLD liver fibrosis/cirrhosis chronic viral hepatitides liver–microbiome axis organokine crosstalk chronobiology liver aging thema EDItEUR::P Mathematics and Science::PS Biology, life sciences Novel Challenges and Therapeutic Options for Liver Diseases |
| title | Novel Challenges and Therapeutic Options for Liver Diseases |
| title_full | Novel Challenges and Therapeutic Options for Liver Diseases |
| title_fullStr | Novel Challenges and Therapeutic Options for Liver Diseases |
| title_full_unstemmed | Novel Challenges and Therapeutic Options for Liver Diseases |
| title_short | Novel Challenges and Therapeutic Options for Liver Diseases |
| title_sort | novel challenges and therapeutic options for liver diseases |
| topic | microbiome obesity metabolic syndrome fecal microbiota transplantation ROTEM® TIPS liver disease thrombosis risk assessment hypercoagulable state portal hypertension hepatic decompensation chronic hepatitis B chronic hepatitis C chronic hepatitis D antiviral therapy liver cirrhosis DAA therapy functional cure HBsAg loss hepatology liver transplantation decompensated cirrhosis acute-on-chronic liver failure NASH pNRF2 SOCS3 immunohistochemistry UDCA bile acid transporter ALT GGT TE neuroendocrine transplantation outcomes liver metastases systematic review prevention management telemedicine metabolic dysfunction-associated fatty liver disease monitor lifestyle modification COVID-19 pandemic NUC treatment low-level HBsAg carriers therapeutic vaccination third generation pre-S/S vaccine long-term observation hepatocellular carcinoma HCC MASLD MASH NAFLD biomarker intestinal microbiota chronic hepatitis b HBsAg seroconversion seroclearance history of hepatology MASLD/NAFLD liver fibrosis/cirrhosis chronic viral hepatitides liver–microbiome axis organokine crosstalk chronobiology liver aging thema EDItEUR::P Mathematics and Science::PS Biology, life sciences |
| topic_facet | microbiome obesity metabolic syndrome fecal microbiota transplantation ROTEM® TIPS liver disease thrombosis risk assessment hypercoagulable state portal hypertension hepatic decompensation chronic hepatitis B chronic hepatitis C chronic hepatitis D antiviral therapy liver cirrhosis DAA therapy functional cure HBsAg loss hepatology liver transplantation decompensated cirrhosis acute-on-chronic liver failure NASH pNRF2 SOCS3 immunohistochemistry UDCA bile acid transporter ALT GGT TE neuroendocrine transplantation outcomes liver metastases systematic review prevention management telemedicine metabolic dysfunction-associated fatty liver disease monitor lifestyle modification COVID-19 pandemic NUC treatment low-level HBsAg carriers therapeutic vaccination third generation pre-S/S vaccine long-term observation hepatocellular carcinoma HCC MASLD MASH NAFLD biomarker intestinal microbiota chronic hepatitis b HBsAg seroconversion seroclearance history of hepatology MASLD/NAFLD liver fibrosis/cirrhosis chronic viral hepatitides liver–microbiome axis organokine crosstalk chronobiology liver aging thema EDItEUR::P Mathematics and Science::PS Biology, life sciences |
| url | ONIX_20240704_9783725815289_233 |